Mirador Therapeutics, an immune-disease biotech with more than $650 million in VC funding, began disclosing pipeline details after reaching a deal tied to a candidate intended to compete with Novartis’ Tavneos. The agreement is part of Mirador’s broader effort to translate preclinical assets into differentiated clinical programs.